Dyadic International Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在生物技术与医疗研究行业排名141/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价5.00。中期看,股价处于下降通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Dyadic International Inc评分
相关信息
行业排名
141 / 404
全市场排名
264 / 4582
所属行业
生物技术与医疗研究
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
5.000
目标均价
+405.05%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Dyadic International Inc亮点
亮点风险
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
公司代码DYAI
公司Dyadic International Inc
CEOEmalfarb (Mark A)
网址https://dyadic.com/
常见问题
Dyadic International Inc(DYAI)的当前股价是多少?
Dyadic International Inc(DYAI)的当前股价是 1.000。
Dyadic International Inc的股票代码是什么?
Dyadic International Inc的股票代码是DYAI。
Dyadic International Inc股票的52周最高点是多少?
Dyadic International Inc股票的52周最高点是2.143。
Dyadic International Inc股票的52周最低点是多少?
Dyadic International Inc股票的52周最低点是0.711。
Dyadic International Inc的市值是多少?
Dyadic International Inc的市值是36.18M。
Dyadic International Inc的净利润是多少?
Dyadic International Inc的净利润为-5.81M。
现在Dyadic International Inc(DYAI)的股票是买入、持有还是卖出?
根据分析师评级,Dyadic International Inc(DYAI)的总体评级为买入,目标价格为5.000。
Dyadic International Inc(DYAI)股票的每股收益(EPS TTM)是多少
Dyadic International Inc(DYAI)股票的每股收益(EPS TTM)是-0.220。